140 related articles for article (PubMed ID: 32346078)
21. A triple-drug combination to prevent nausea and vomiting following BEAM chemotherapy before autologous hematopoietic stem cell transplantation.
Pielichowski W; Barzal J; Gawronski K; Mlot B; Oborska S; Wasko-Grabowska A; Rzepecki P
Transplant Proc; 2011 Oct; 43(8):3107-10. PubMed ID: 21996238
[TBL] [Abstract][Full Text] [Related]
22. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetic profile and safety of intravenous NEPA, a fixed combination of fosnetupitant and palonosetron, in cancer patients: Prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy.
Kurteva G; Chilingirova N; Rizzi G; Caccia T; Stella V; Bernareggi A
Eur J Pharm Sci; 2019 Nov; 139():105041. PubMed ID: 31404621
[TBL] [Abstract][Full Text] [Related]
24. Combined use of multiday palonosetron with aprepitant and low-dose dexamethasone in prevention of nausea and emesis among patients with multiple myeloma and lymphoma undergoing autologous hematopoietic stem cell transplant: A pilot study.
Deauna-Limayo D; Aljitawi OS; Ganguly S; Abhyankar S; Wick JA; McGuirk JP
J Oncol Pharm Pract; 2014 Aug; 20(4):263-9. PubMed ID: 24005093
[TBL] [Abstract][Full Text] [Related]
25. Multiple-day administration of fosaprepitant combined with tropisetron and olanzapine improves the prevention of nausea and vomiting in patients receiving chemotherapy prior to autologous hematopoietic stem cell transplant: a retrospective study.
Ye P; Pei R; Wang T; Cao J; Zhang P; Chen D; Liu X; Du X; Li S; Tang S; Hu Y; Jiang L; Lu Y
Ann Hematol; 2022 Aug; 101(8):1835-1841. PubMed ID: 35668198
[TBL] [Abstract][Full Text] [Related]
26. Safety and efficacy of netupitant/palonosetron and dexamethasone in classical Hodgkin's lymphoma patients with inadequate chemotherapy-induced nausea and vomiting prophylaxis with palonosetron and dexamethasone: a single-center real-life experience.
Zilioli VR; Muzi C; Minga P; Codega P; Crucitti L; Meli E; Esposito A; Panico C; Rusconi C; Cairoli R
Int J Hematol Oncol; 2020 Feb; 9(1):IJH23. PubMed ID: 32382409
[TBL] [Abstract][Full Text] [Related]
27. Preventing chemotherapy-induced nausea and vomiting in patients with lung cancer: efficacy of NEPA (netupitant-palonosetron), the first combination antiemetic.
Hesketh PJ; Palmas M; Nicolas P
Support Care Cancer; 2018 Apr; 26(4):1151-1159. PubMed ID: 29080920
[TBL] [Abstract][Full Text] [Related]
28. Review of oral fixed-dose combination netupitant and palonosetron (NEPA) for the treatment of chemotherapy-induced nausea and vomiting.
Lorusso V; Karthaus M; Aapro M
Future Oncol; 2015; 11(4):565-77. PubMed ID: 25360998
[TBL] [Abstract][Full Text] [Related]
29. Comparison of netupitant/palonosetron with 5-hydroxytryptamine-3 receptor antagonist in preventing of chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation.
Zhang H; Zeng Q; Dong T; Chen X; Kuang P; Li J; Wu Q; Liu T; Niu T; Liu Z; Ji J
Front Oncol; 2023; 13():1280336. PubMed ID: 38074658
[TBL] [Abstract][Full Text] [Related]
30. Palonosetron, aprepitant, and dexamethasone for prevention of nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: A phase II study.
Isoda A; Saito R; Komatsu F; Negishi Y; Oosawa N; Ishikawa T; Miyazawa Y; Matsumoto M; Sawamura M; Manaka A
Int J Hematol; 2017 Apr; 105(4):478-484. PubMed ID: 27873176
[TBL] [Abstract][Full Text] [Related]
31. Timing flexibility of oral NEPA, netupitant-palonosetron combination, administration for the prevention of chemotherapy-induced nausea and vomiting (CINV).
Baron-Hay S; Aapro M; Bernareggi A; Schwartzberg L
Support Care Cancer; 2019 Apr; 27(4):1309-1317. PubMed ID: 30685793
[TBL] [Abstract][Full Text] [Related]
32. Advances in the Management of Chemotherapy-Induced Nausea and Vomiting: New Data From Recent and Ongoing Trials.
Roeland E; Aapro MS; Schwartzberg LS
Clin Adv Hematol Oncol; 2015 Oct; 13(10 Suppl 10):1-14. PubMed ID: 26859507
[TBL] [Abstract][Full Text] [Related]
33. Palonosetron (Aloxi) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy.
Musso M; Scalone R; Bonanno V; Crescimanno A; Polizzi V; Porretto F; Bianchini C; Perrone T
Support Care Cancer; 2009 Feb; 17(2):205-9. PubMed ID: 18839220
[TBL] [Abstract][Full Text] [Related]
34. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.
Natale JJ
Hosp Pract (1995); 2015; 43(4):226-34. PubMed ID: 26308912
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
[TBL] [Abstract][Full Text] [Related]
36. Prevention of chemotherapy-induced nausea: the role of neurokinin-1 (NK
Bošnjak SM; Gralla RJ; Schwartzberg L
Support Care Cancer; 2017 May; 25(5):1661-1671. PubMed ID: 28108820
[TBL] [Abstract][Full Text] [Related]
37. Efficacy benefit of an NK1 receptor antagonist (NK1RA) in patients receiving carboplatin: supportive evidence with NEPA (a fixed combination of the NK1 RA, netupitant, and palonosetron) and aprepitant regimens.
Jordan K; Gralla R; Rizzi G; Kashef K
Support Care Cancer; 2016 Nov; 24(11):4617-25. PubMed ID: 27334131
[TBL] [Abstract][Full Text] [Related]
38. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
Navari RM
J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
[TBL] [Abstract][Full Text] [Related]
39. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
Aapro MS; Grunberg SM; Manikhas GM; Olivares G; Suarez T; Tjulandin SA; Bertoli LF; Yunus F; Morrica B; Lordick F; Macciocchi A
Ann Oncol; 2006 Sep; 17(9):1441-9. PubMed ID: 16766588
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of palonosetron plus dexamethasone in preventing chemotherapy-induced nausea and emesis in patients receiving carboplatin-based chemotherapy for gynecologic cancers: a phase II study by the West Japan Gynecologic Oncology Group (WJGOG 131).
Nishio S; Aihara S; Shimokawa M; Fujishita A; Taniguchi S; Hachisuga T; Yanazume S; Kobayashi H; Murakami F; Numa F; Kotera K; Okura N; Toki N; Yokoyama M; Ushijima K
J Gynecol Oncol; 2018 Sep; 29(5):e77. PubMed ID: 30022637
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]